ABOUT FOLIGO

One hundred and eighty thousand women suffer from ovarian cancer in the United States alone. Most ovarian malignancies are epithelial ovarian cancer (EOC) and diagnosed at an advanced stage of disease where the cancer has spread from the ovaries to other pelvic and abdominal organs. Primary EOC treatment in the US involves surgical removal of palpable tumors followed by combination chemotherapy. While most women achieve clinical remission with standard treatment, approximately 80% of all late-stage EOC recurs and is untreatable. New treatments are imperative to improve the response and survival outcome for women diagnosed with late-stage EOC. FOLIGO is responding to this need.

The Company’s lead compound, FOLIGO 001, is designed to inhibit the protein production of a cancer-promoting gene that is present in EOC and many other types of cancers, but is absent from almost all normal tissues. FOLIGO 001 will be utilized initially for the treatment of EOC. Foligo’s aim is to enable classical chemotherapy to work more efficiently by making target cancer cells more vulnerable to chemotherapeutics. This increases survival while decreasing negative side effects in patients.